{"slideshow_credits": null, "snippet": "As the Valeant case shows, the proliferation of results not stated according to generally accepted accounting principles makes it harder for investors to evaluate performance.", "abstract": "Gretchen Morgenson Fair Game column contends beleaguered pharmaceutical firm Valeant is one of growing number of companies that offer two kinds of financial results; holds there are those that comply with accepted accounting principles, and those that help executives spin earnings and lull investors.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Gretchen", "role": "reported", "lastname": "MORGENSON", "rank": 1, "organization": ""}], "original": "By GRETCHEN MORGENSON"}, "web_url": "http://www.nytimes.com/2015/11/01/business/valeant-shows-the-perils-of-fantasy-numbers.html", "lead_paragraph": "As the Valeant case shows, the proliferation of results not stated according to generally accepted accounting principles makes it harder for investors to evaluate performance.", "headline": {"print_headline": "Valeant\u2019s Fantastic(al) Numbers", "main": "Valeant Shows the Perils of Fantasy Numbers", "content_kicker": "Fair Game", "kicker": "Fair Game"}, "_id": "56339f5538f0d85e68a21d0b", "word_count": "1243", "multimedia": [{"height": 126, "url": "images/2015/10/30/business/30valeant/30valeant-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/10/30/business/30valeant/30valeant-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 400, "url": "images/2015/10/30/business/30valeant/30valeant-articleLarge.jpg", "legacy": {"xlarge": "images/2015/10/30/business/30valeant/30valeant-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/10/30/business/30valeant/30valeant-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/10/30/business/30valeant/30valeant-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-11-01T00:00:00Z", "source": "The New York Times", "news_desk": "SundayBusiness", "keywords": [{"name": "organizations", "value": "Valeant Pharmaceuticals International Inc", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Accounting and Accountants", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Regulation and Deregulation of Industry", "is_major": "N", "rank": "3"}, {"name": "subject", "value": "Company Reports", "is_major": "N", "rank": "4"}, {"name": "organizations", "value": "Securities and Exchange Commission", "is_major": "N", "rank": "5"}, {"name": "subject", "value": "Stocks and Bonds", "is_major": "N", "rank": "6"}], "blog": [], "subsection_name": null, "type_of_material": "News"}